NL-OMON45792已完成3 期
Pulmonary NTM disease: A regimen of ethambutol and azithromycin with as adjunctive rifampicin vs clofazimine. - PERC
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 124
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- ATS diagnostic criteria for nodular bronchiectatic or fibro-cavitary MAC-PD met, i.e. symptomatic, fibro-cavitary lesions, bronchiectasis or nodules seen on X-ray or (HR)CT scan of the lungs and *2 positive cultures of the same M. avium complex species (Griffith et al., 2007).
- •- At least one of the positive cultures must be done in the last 4 months before inclusion.
- •- Age > 18 years.
- •- Signed and dated patient informed consent.
- •- Patients can be included in spite of previous treatment if treatment was conform ATS-guidelines and they did not receive any treatment in the last 2 months.
排除标准
- •- Extensive cavitary MAC-PD defined as cavitary lesions in two or more lobes with the smallest cavity having a diameter >3 centimetre, measured from Computed Tomography (CT) images or when physician deems it favourable to treat the patient with additional amikacine
- •- Macrolide-resistant MAC strain isolated at the time of diagnosis.
- •- A relevant medical history or current condition that might interfere with drug absorption, distribution, metabolism or excretion.
- •- Use of concomitant drugs that interfere with the pharmacokinetics of the study drugs.
- •- HIV infected.
- •- Diagnosed with cystic fibrosis.
- •- Pregnant or breastfeeding or inadequate contraceptive measures (if applicable).
- •- ALAT > 3 times the upper limit of normal.
- •- ASAT > 3 times the upper limit of normal.
- •- An abnormal serum creatinine level (defined as a level that is higher than the upper limit of normal).
- •- Active pulmonary malignancy (primary or metastatic) or any other malignancy requiring chemotherapy or radiotherapy within 1 year before screening or anticipated during the study period.
- •- - Use of drugs for co-morbid conditions that have interactions with any of the drugs in the study and that cannot be safely exchanged for an alternative drug for which such interactions are not known to occur; this is only applicable if these others drugs lower one of study drugs or cause safety issues; such as medication that causes QTc interval prolongation; such as bedaquiline, antidepressants, antiarrhythmics or fluoroquinolones, voriconazole, protease inhibitors
- •- Active alcohol abuse.
- •- Hypersensitivity to one of the study drugs.
- •- Patients with previous failure of treatment for MAC-PD, defined as persistent culture positivity despite >6 months of guideline-recommended treatment.
研究者
相似试验
进行中（未招募）
1 期
Research to assess effectiveness of treatment of pumonary infections with M.avium complexFibrocavitary pulmonary disease caused by M.avium complexEUCTR2015-003786-28-NLRadboudumc123
招募中
不适用
To assess the prevalence of Optic neuropathy due to the commonly used anti tubercular drug- Ethambutol and to study whether steroids have any role in treating it.CTRI/2021/02/031606Indian Council of Medical ResearchICMR
招募中
不适用
Observational study for pulmonary nontuberculous mycobacterial infection and non-cystic fibrosis bronchiectasis.Pulmonary nontuberculous mycobacterial disease and non-cystic fibrosis bronchiectasisJPRN-UMIN000007546Keio University Hospital2,700
尚未招募
不适用
Outcome Of Pulmonary Tuberculosis In Children And Adolescents Treated With Daily Drug Regimen Of Anti Tuberculosis TreatmentCTRI/2022/12/047837Department of Paediatrics
进行中（未招募）
不适用
Everolimus in der Therapie von Patienten mit pulmonaler Hypertonie-steady or progressive pulmonary hypertension accompanied by at least two of the following parameters associated with a poor prognosis:-Cardiac index = 2,1 l/min/m2-6 MWD = 380 m-systolic RR = 120 mmHg-VO2max = 11 l/min/kg-SVO2 = 60%-Hf = 90/min-probabilty of survival for one year = 0,7 following the NIH-formularMedDRA version: 8.1Level: PTClassification code 10037400Term: Pulmonary hypertensionEUCTR2006-004224-37-DEniversität Leipzig10